Name: Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Dosage forms and strengths
Published: 2026-09-17T18:16:08-04:00

Product information and disease description Product description Product information

Dosage forms and strengths

5 evidence topics · 3 sources

United States: tablets and powder for oral suspension

“Each tablet contains 100 mg of tovorafenib.” (opens the source at this quote in a new tab)
“25 mg/mL: white to off white powder. After reconstitution, each mL of strawberry flavored tovorafenib suspension contains 25 mg of tovorafenib. Each bottle delivers 300 mg of tovorafenib in 12 mL.” (opens the source at this quote in a new tab)

United States: tablet carton configurations by weekly dose

Weekly dose	Each carton contains	Each blister card contains	NDC
400 mg	“4 blister cards”	“four 100 mg tablets”	“NDC 82950-001-16”
500 mg	“4 blister cards”	“five 100 mg tablets”	“NDC 82950-001-20”
600 mg	“4 blister cards”	“six 100 mg tablets”	“NDC 82950-001-24”

United States: oral suspension kit

“25 mg/mL: white to off white powder in a clear glass bottle, co-packaged with a press-in bottle adaptor and a 20 mL oral dosing syringe (NDC# 82950-012-01).” (opens the source at this quote in a new tab)
“Suspension must be used immediately after reconstitution.” (opens the source at this quote in a new tab)

European Union: film-coated tablets and powder for oral suspension

“Each film-coated tablet contains 100 mg tovorafenib.” (opens the source at this quote in a new tab)
“Each carton contains 16, 20 or 24 film-coated tablets.” (opens the source at this quote in a new tab)
“One bottle of Ojemda contains 300 mg of tovorafenib. After reconstitution, one bottle of oral suspension delivers 12 ml of tovorafenib at a concentration of 25 mg/ml.” (opens the source at this quote in a new tab)

Japan: tablets and dry syrup

“Ojemda® Tablets 100 mg and Ojemda Dry Syrup 300 mg (generic name: tovorafenib)” (opens the source at this quote in a new tab)